The findings of anti-ETAR and anti-ETBR autoantibodies are driving factors skewing subjects toward an SLE diagnosis and highlight the potential utility of these biomarkers as a biosignature for SLE-associated vascular dysfunction and subsequent inflammation. Here, EDNRA is linked to systemic lupus erythematosus.